1. Home
  2. VBNK vs XERS Comparison

VBNK vs XERS Comparison

Compare VBNK & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VBNK
  • XERS
  • Stock Information
  • Founded
  • VBNK 1980
  • XERS 2005
  • Country
  • VBNK Canada
  • XERS United States
  • Employees
  • VBNK N/A
  • XERS N/A
  • Industry
  • VBNK Commercial Banks
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • VBNK Finance
  • XERS Health Care
  • Exchange
  • VBNK Nasdaq
  • XERS Nasdaq
  • Market Cap
  • VBNK 441.5M
  • XERS 526.3M
  • IPO Year
  • VBNK 2021
  • XERS 2018
  • Fundamental
  • Price
  • VBNK $12.69
  • XERS $3.75
  • Analyst Decision
  • VBNK Strong Buy
  • XERS Strong Buy
  • Analyst Count
  • VBNK 3
  • XERS 4
  • Target Price
  • VBNK $19.00
  • XERS $5.15
  • AVG Volume (30 Days)
  • VBNK 87.6K
  • XERS 1.8M
  • Earning Date
  • VBNK 03-05-2025
  • XERS 03-05-2025
  • Dividend Yield
  • VBNK 0.57%
  • XERS N/A
  • EPS Growth
  • VBNK N/A
  • XERS N/A
  • EPS
  • VBNK 1.07
  • XERS N/A
  • Revenue
  • VBNK $80,302,117.00
  • XERS $187,361,000.00
  • Revenue This Year
  • VBNK N/A
  • XERS $25.11
  • Revenue Next Year
  • VBNK $40.97
  • XERS $19.29
  • P/E Ratio
  • VBNK $14.89
  • XERS N/A
  • Revenue Growth
  • VBNK 3.59
  • XERS 22.72
  • 52 Week Low
  • VBNK $9.48
  • XERS $1.69
  • 52 Week High
  • VBNK $18.38
  • XERS $4.10
  • Technical
  • Relative Strength Index (RSI)
  • VBNK 31.84
  • XERS 57.32
  • Support Level
  • VBNK $13.36
  • XERS $3.51
  • Resistance Level
  • VBNK $13.86
  • XERS $4.10
  • Average True Range (ATR)
  • VBNK 0.44
  • XERS 0.17
  • MACD
  • VBNK -0.07
  • XERS 0.03
  • Stochastic Oscillator
  • VBNK 2.21
  • XERS 46.15

About VBNK VersaBank

VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Share on Social Networks: